Provenance Record

Well structured (Overview / What We Know / What We Don't Know / Analysis). Neutral tone. No AI self-reference. Length appropriate for News (930 words). Strong cross-reference to prior published article 2026-04/15-revolution-medicines-daily-pill-daraxonrasib... (verified to exist).

{"source-0":{"url":"https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug","snapshot":"source-0.html.gz","status":"FDA press release dated May 1, 2026 (datetime metadata confirmed). Verifies: April 28 receipt, April 30 signing, 'safe to proceed' letter, Makary quote verbatim, RMC-6236 drug code, Breakthrough Therapy + Orphan Drug designations granted previously, CNPV in October 2025."},"source-1":{"url":"https://www.dana-farber.org/newsroom/news-releases/2026/rason-inhibitor-daraxonrasib-shows-promising-results-in-advanced-pancreatic-cancer-phase-12-study","snapshot":"source-1.html.gz","status":"Dana-Farber news release dated May 6, 2026. Verifies: NEJM publication, 168 patients, 300 mg dose, ~30% ORR with one prior line, 8-month median DoR, Wolpin direct quotes verbatim, Hale Family Center affiliation, molecular glue + cyclophilin A mechanism, RAS-mutant trial population. DOES NOT contain '96% AE rate' or 'grade ≥3 in 30%' — only says 'all patients experienced some side effects'. DOES NOT contain trial code 'RMC-6236-001'."},"source-2":{"url":"https://pancan.org/news/first-ras-inhibitor-extends-survival-in-previously-treated-metastatic-pancreatic-adenocarcinoma-what-you-need-to-know/","snapshot":"source-2.html.gz","status":"PanCAN explainer page. Verifies: NCT07573215 EAP trial number, NCT06625320 RASolute 302 number, 'moving as quickly as possible / safe and equitable access' Revolution Medicines statement, Anna Berkenblit quote 'real opportunity to bring new hope' verbatim, CNPV designation, ASCO presentation. DOES NOT contain 'RASolute 303' trial name."}}

Article's core story (NEJM Phase 1/2 publication + FDA Expanded Access authorization) is solid: every direct quote (Wolpin x2, Makary, Berkenblit, Revolution Medicines statement) appears verbatim in the cited snapshots; all major clinical specifics (168 patients, 300 mg, ~30% ORR, ~90% disease control, 8-month median DoR, May 6 NEJM date, April 28/30 + May 1 FDA timeline, NCT07573215, Breakthrough Therapy + Orphan Drug + CNPV designations, ASCO May 31 plenary) are verified. The article fabricates four specifics — most consequentially the 96% AE rate and grade ≥3 in 30% safety numbers, which are central quantitative clinical claims. APPROVE_WITH_CORRECTIONS with a detailed corrections record covering the unsourced specifics.